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 Abstract 
 Background: COPD pathology involves not only the lungs but also extrapulmonary 
abnormalities. Osteoporosis is one of the most important abnormalities because 
it may cause vertebral compression fractures and deteriorate pulmonary function. 
COPD patients have many risk factors for osteoporosis, such as low BMI, decreased 
activity, systemic infl ammation, and use of corticosteroids. Some of these 
factors have been shown to deteriorate with COPD exacerbations. We previously 
demonstrated the correlation between emphysema and osteoporosis and between 
emphysema progression and COPD exacerbations. Thus, the hypothesis that 
exacerbation causes osteoporosis progression in COPD patients was investigated. 
 Methods: Forty-two COPD patients not on osteoporosis treatment for over 2 years 
were recruited. During follow-up, exacerbations had been prospectively recorded. 
Thoracic vertebral bone mineral density (BMD) was measured using chest CT, and 
the annual change in BMD was calculated. The change was compared between 
patients with and without a history of exacerbations.  Results: The decrease in 
thoracic vertebral BMD was greater in patients with than in those without a 
history of exacerbations (median ΔBMD mg/ml⋅year: –3.78 versus –0.30, p = 
0.02). Moreover, multivariate regression analysis showed that exacerbations and 
baseline PaO 2 were independent predictors of the BMD decrease (R 
2 = 0.20, p = 
0.007, and R 2 = 0.09, p = 0.03, respectively) after adjustment for baseline age, 
smoking status, and airfl ow limitation. Conclusions: This is the fi rst longitudinal 
study to demonstrate that COPD exacerbations are independently associated with 
osteoporosis progression. Osteoporosis progression should be evaluated in COPD 
patients, especially in those with a history of frequent exacerbations. 
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 Introduction 
 Th e pathology of COPD involves not only the lungs but also extrapulmonary 
abnormalities such as diabetes, cachexia, skeletal muscle wasting, and ane-
mia ( 1 ). Of these, osteoporosis is one of the most important abnormalities 
 Keywords:  Exacerbation ,  Osteoporosis ,  Bone 
mineral density ,  Chronic obstmetive pulmonary 
disease ,  Emphysema. 
 Abbreviations 
 BMD  bone mineral density ;  BMI  body mass index ;  COPD  chronic obstructive pulmonary disease ;  CT  computed 
tomography ;  D LCO ,  diffusion capacity of carbon monoxide ;  ECLIPSE  Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate End-points study (ECLIPSE study) ;  FEV 1  forced expiratory volume in 1 second ;  GOLD  the 
Global Initiative for Chronic Obstructive Lung Disease ;  ICS  inhaled corticosteroid ;  IL-6  interleukin-6 ;  LAA  low 
attenuation area ;  PaO 2  partial pressure of oxygen in arterial blood ;  RANKL,  receptor activator of nuclear factor 
kappa-B ligand ;  ROI  region of interest ;  TNF-α  tumor necrosis factor α ;  V A  alveolar ventilation ;  VCF  vertebral 
compression fracture. 
LCPD_A_650243.indd   235 5/12/12   1:11:25 AM
Copyright © 2012 Informa Healthcare USA, Inc
236 H. Kiyokawa et al.
because it may cause vertebral compression fractures 
(VCF) that can deteriorate pulmonary function. It has 
been reported that the prevalence of VCF in COPD 
patients is high (24% to 63%) ( 2 ), and one compression 
fracture in the thoracic vertebra results in a 9% decrease 
in vital capacity and impairment in FEV 1 in COPD 
patients ( 3,4 ). 
 Th e common features in COPD patients, such as low 
body mass index (BMI), history of smoking, age, inac-
tivity, systemic infl ammation, and the use of systemic 
corticosteroids, are important risk factors for osteopo-
rosis ( 3 ). Moreover, we previously reported that severity 
of emphysema was closely related to loss of vertebral 
bone mineral density (BMD) assessed by chest com-
puted tomography (CT) scan ( 5 ), and our fi ndings were 
subsequently confi rmed by other investigators using 
conventional osteoporosis indices (Dual-emission X-ray 
absorptiometry) ( 6 ). Th ese fi ndings suggest that COPD 
pathology is closely linked to osteoporosis. 
 Exacerbation is an important issue in COPD because 
it has negative impacts on FEV 1 ( 7,8 ), health status ( 9 ), 
survival ( 10,11 ), the BODE index ( 12 ), and socioeco-
nomic costs ( 13 ). Exacerbations also cause deterioration 
in several risk factors for osteoporosis, such as inactivity 
( 12 ) and systemic infl ammation ( 14 ), and the use of sys-
temic corticosteroids during exacerbations may acceler-
ate BMD loss ( 11 ). Moreover, we recently reported that 
exacerbations accelerated emphysematous change ( 15 ). 
Th us, we speculated that exacerbations may accelerate 
not only parenchymal destruction but also BMD loss. 
However, to the best of our knowledge, no longitudinal 
study has examined the relationship between COPD 
exacerbations and osteoporosis progression. 
 Using chest CT scan images, BMD of the thoracic 
vertebrae and emphysematous changes can be evaluated 
simultaneously ( 16,17 ). Moreover, BMD of the vertebra 
assessed by chest CT scan is better than that assessed 
by dual X-ray absorption to predict vertebral VCFs ( 18 ). 
In the present study, the longitudinal impact of exacer-
bations on thoracic vertebral BMD was explored using 
chest CT scan data. 
 Methods 
 Subjects 
 Th is is a part of prospective observational study investi-
gating COPD exacerbation ( 12 , 15 , 19 ). Th e patient inclu-
sion criteria were: ( 1 ) COPD diagnosed according to the 
criteria of the Global Initiative for Chronic Obstructive 
Lung Disease ( 1 ); and ( 2 ) the patient agreed to prospec-
tively record exacerbations. Th e exclusion criteria were: 
( 1 ) history of respiratory diseases other than COPD; ( 2 ) 
occurrence of malignancy within the previous 5 years; ( 3 ) 
history of bone disease; ( 4 ) receiving osteoporosis treat-
ment such as bisphosphonates and alfacalcidol (vitamin 
D analogue); ( 5 ) currently receiving oral systemic corti-
costeroid therapy; ( 6 ) receiving rehabilitation during the 
study; and ( 7 ) receiving home-oxygen therapy. 
 Th e study protocol is summarized in Figure  1 , and 
the details of patient disposition are provided in the 
result section. Briefl y, from March 2006 to May 2008, 
we enrolled 82 of 104 patients with COPD who agreed 
to record exacerbations prospectively. Th e observation 
period was 2 years. Finally, follow-up CT scans were 
performed 2 years after study entry in 42 patients. Th e 
subject population in the present study was almost the 
same as in our previous study ( 15 ). Th e most notable dif-
ference between the two study populations was related 
to whether the patients receiving osteoporosis therapy 
were excluded. Th e ethics committee of Kyoto University 
approved the study (approval No. E182), and all patients 
provided their written informed consent to participate 
 Exacerbation criteria and defi nition 
of stable condition 
 Exacerbations were defi ned as symptomatic deterioration 
requiring medical treatment (antibiotics and/or systemic 
corticosteroids) ( 15 , 19 , 20 ). Stable condition was defi ned 
as an exacerbation-free interval that lasted for more than 
4 weeks. Symptomatic changes were assessed by a modi-
fi ed version of the East London cohort study criteria ( 7 ). 
 Pulmonary function tests, CT 
acquisition, and calibration of CT 
numbers 
 Baseline and 2-year follow-up CT scans (Aquilion 64; 
Toshiba, Tokyo, Japan; slice thickness, 0.5 mm) and pul-
monary function tests (Chestac-65V; Chest MI Corp, 
Tokyo, Japan) were performed under stable conditions. All 
pulmonary function tests and CT scans were performed 
after inhaling short-acting bronchodilators (salbutamol 
and ipratropium) as previously reported ( 5 , 21 ). CT num-
bers in the lung fi eld were corrected using tracheal air 
density to prevent the X-ray tube aging eff ect ( 15 , 22 ). 
 Analysis of low attenuation areas 
 To evaluate pulmonary emphysema quantitatively, the 
low attenuation area percentage (LAA%) was measured 
according to our previous reports ( 5 , 23 ). 
 Measurement of BMD in vertebral 
bone 
 Using a modifi ed method reported previously ( 5 , 17 ), 
BMD was measured in the thoracic vertebral bones (T4, 
T7, T10) derived from the CT scan density. In a previous 
report, BMD was calculated using one chest CT scan 
slice, but in the present study, it was calculated using 
fi ve chest CT scan slices. Briefl y, fi rst a mid-vertebral 
slice was selected using reconstructed images (sagittal 
and coronal images) from 0.5-mm slice thickness CT 
images. Th en, the elliptical region of interest (ROI) was 
encompassed manually as the largest possible area at 
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the anterior portion of each vertebral body on fi ve slices 
whose center was the chosen mid-vertebral slice. 
 Finally, the mean CT scan density of the ROI was 
measured. As in our previous report ( 5 ), BMD was calcu-
lated based on mean CT scan density using the formula 
(BMD (in milligrams per milliliter) = 0.767 × CT scan 
density (in HU) + 3.37). Th is calculating formula was val-
idated in our previous report using calibration phantom 
which contained eight tubes of known concentration of 
hydroxyapatite ( 5 ). All images were measured by two pul-
monologists (H.K. and N.T.) to minimize interobserver 
variability of the measurements, and their measurements 
were then averaged to obtain fi nal values. 
 Measurement of the change in BMD 
 Th e annual change in BMD (ΔBMD) was defi ned as fol-
lows: 
ΔBMD (in milligrams per milliliter per year ) 
= ((BMD after two-year follow-up)-
  (BMD at baseline)) / (follow-up span (in years)). 
 Annual BMD percentage change normalized with 
baseline BMD was adjusted as follows:
ΔBMD/base (in percentage per year) 
= (ΔBMD/(BMD at baseline)) × 100 
 Statistical analyses 
 All statistical analyses were performed using JMP 7 soft-
ware (SAS Institute; Cary, NC). Th e data are expressed 
as medians (25 th , 75 th percentile) unless otherwise indi-
cated. Th e diff erences between groups were evaluated 
using the Mann-Whitney U-test. Data within groups 
were analyzed with the Wilcoxon signed-rank test. Rela-
tionships among data were assessed by Spearman’s rank 
correlation test. To evaluate the relative contribution 
of exacerbations to the decrease in thoracic vertebral 
BMD, multivariate regression analysis was performed. 
A  p- value less than 0.05 was considered signifi cant. 
 Results 
 Patient characteristics 
 Baseline CT scans were performed on 82 patients who 
had participated in our prospective observational study 
investigating COPD ( 15 , 19 , 20 ). Of these patients, 14 
 Figure 1.   Patient disposition and reasons for exclusion. COPD, chronic obstructive pulmonary disease; CT, computed tomography. 
155 stable COPD patients visited Kyoto university hospital 
From March 2006 to May 2008 
104 patients participated in prospective observational study 
investigating COPD exacerbation  
4 patients did not agree to undergo a CT scan 
18 patients were excluded because of exclusion 
criteria 
82 enrolled patients: Baseline CT scan 
14 patients were excluded because of abnormal 
h t h d th th h tf ll c es  s a ow o er an emp ysema ous
change 
2-year o ow-up 
26 patients were excluded because of 
8  Withdrawal of consent 
4  Appearance of new shadow 
  on chest images 
5  Serious condition 
4  death 
2  vertebra bone fracture 
3  loss to follow-up 
42 patients completed follow-up CT scan and this study 
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were excluded because of abnormal chest shadows not 
associated with emphysematous changes seen on chest 
CT images at entry (Figure  1 ). Over the two-year follow-
up, 26 patients were excluded for the following reasons: 
withdrawal of consent, appearance of a new shadow, 
serious condition, death, vertebral bone fracture, or 
lost to follow-up. Table  1 shows the characteristics of 
the study subjects (42 patients) who completed all of the 
follow-up examinations, including baseline and 2-year 
follow-up chest CT scans. During the observational 
period, 13 patients experienced exacerbations requiring 
treatment with antibiotics and/or systemic corticos-
teroids at least once, and 29 patients experienced no 
exacerbations. Of 13 patients with a history of exacer-
bations, only 1 patient received systemic corticosteroid 
treatment (methylprednisolone 16 mg/day for 5 days). 
Th ere were no signifi cant diff erences in baseline clini-
cal parameters, pulmonary function, CT parameters, or 
BMD between the groups (Table  2 ). Baseline pharmaco-
logical treatment including inhaled corticosteroids was 
not signifi cantly diff erent between the groups. 
 Impact of exacerbations on BMD, 
lung functions, and emphysematous 
change 
 Changes in BMD, lung functions, emphysematous 
change, and PaO 2 between patients with and without a 
history of exacerbations are shown in Table  3 . In patients 
who experienced exacerbations, BMD and BMD/base 
decreased signifi cantly after the follow-up period, 
whereas these parameters did not change in patients 
who experienced no exacerbations. Th e median annual 
changes in BMD and BMD/base were signifi cantly 
greater in patients with than in those without exacerba-
tions (ΔBMD mg/ml·year: −3.78 versus −0.30, p = 0.01, 
ΔBMD/base %: −5.41 versus −0.60, p = 0.02) (Table  2 , 
Figure  2 ).  
 In agreement with our previous report (15), LAA% 
also increased signifi cantly after the observation period 
in patients who experienced exacerbations (p = 0.01) 
(Table  3 ), whereas this parameter did not change in 
patients who experienced no exacerbations. Th ere were 
no signifi cant annual changes in pulmonary function 
test results such as FEV 1 and D LCO between the groups. 
 Table  4 shows the correlation between the annual 
change in BMD and associated factors for osteoporo-
sis (exacerbation frequency and factors that have been 
shown to be associated with osteoporosis). Th e annual 
change in BMD was signifi cantly correlated with the 
exacerbation frequency (Spearman’s rank correlation 
coeffi  cient ρ = -0.37, p = 0.02). On univariate analysis, 
baseline FEV 1 was associated with the change in BMD 
(p = 0.04) whereas other factors such as BMI, smoking 
history, %FEV 1 predict, and LAA% were not. 
 On stepwise multivariate regression analysis (Table  5 ) 
to examine the relative contribution of each variable to 
 Table 1.  Baseline characteristics of the study patients (N = 42) 
Characteristics  Values
Age 70.0 (65.0,76.3)
Gender, male : female 39: 3
Height, meter 1.64 (1.60, 1.69)
Weight, kg 57.5 (53.5, 62.0)
Body mass index 21.0 (19.5, 23.3)
Smoking Status current : former 13: 39
Smoking history, pack-year 53.5 (42.5, 88.0)
FEV1, L 1.61 (1.12, 1.94)
%FEV1, % 56.4 (41.8, 69.4)
LAA% (-960), % 32.2 (25.0, 38.1)
DLCO /VA , mL/min/mmHg/L 2.61 (1.84, 3.39)
 Data are expressed as the median (25th, 75th percentile). FEV 1 , forced expiratory volume 
in 1 second; %FEV 1 , FEV 1 % predicted; LAA%, percentage of low attenuation area; 
D LCO /V A , ratio of diffusing capacity to alveolar ventilation. 
 Table 2.  Baseline characteristics of the two groups: Patients with and without 
a history of COPD exacerbations 
 Exacerbation (-) Exacerbation (+) p-value
Subjects 29 13
Exacerbations/year 0 0.50 (0.48, 0.83)
Baseline 
characteristics
 Age, years 66.0 (62.5, 77.5) 72.0 (68.0, 74.0) 0.27
 Gender, male : 
 female
28 : 1 11 : 2 0.22
 Body mass index 21.6 (19.9, 23.0) 20.1 (17.7, 24.3) 0.24
 Smoking Status, 
 current : former
11 : 18 2: 11 0.28
 Smoking history, 
 pack-year
57.0 (42.5, 99.0) 52.0 (41.5, 78.8) 0.57
 FEV1, L 1.64 (1.12, 2.08) 1.45 (1.15, 1.91) 0.64
 %FEV1, % 55.1 (39.3, 72.3) 61.0 (53.5, 66.9) 0.50
GOLD 
classifi cation, n (%)
 stage I 4 (13.8) 1 (7.7)
 stage II 14 (48.3) 10 (76.9)
 stage III 10 (34.4) 1 (7.7)
 stage IV 1 (3.5) 1 (7.7)





LAA% (-960), % 31.8 (24.9, 38.1) 32.6 (24.9, 39.2) 0.87
DLCO /VA , mL/min/
mmHg/L
2.68 (1.86, 3.36) 2.48 (1.43, 3.88) 0.59
PaO2, mmHg 78.9 (73.4, 84.2) 73.7 (70.7, 85.9) 0.64
ICS, Yes:No 4: 25 4 : 9 0.23
Tio, Yes:No 12 : 17 5 : 8 1.00
 Data are expressed as the median (25th, 75th percentile). FEV 1 , forced expiratory volume 
in 1 second; %FEV 1 , FEV 1 % predicted; GOLD, The Global Initiative for Chronic Obstructive 
Lung Disease; BMD, bone mineral density; LAA%, percentage of low attenuation area 
LAA%, percentage of low attenuation area; D LCO /V A , ratio of diffusing capacity to alveolar 
ventilation ICS, ihhaled corticosteroid; Tio, tiotropium. 
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 Table 3.  Annual changes in thoracic vertebral BMD, lung function, and LAA% 
 Exacerbation (-) p-value (within group) Exacerbation (+) p -value (within group) p-value (between groups)
BMD, mg/ml
−0.30 (–1.82, 1.33) 0.41 −3.78 (–5.81, –0.29) 0.002 0.01
BMD/base, %
−0.60 (–3.07, 2.63) 0.39 −5.41 (–10.6, –0.36) 0.002 0.02
BMI 0.00 (–0.53, 0.38) 0.65
−0.78 (–1.49, 0.70) 0.34 0.38
FEV1, mL −51.4 (–117.0, –7.7) 0.0001 −75.0 (–97.9, –4.7) 0.0005 0.72
%FEV1, % 0.28 (–2.08,2.15) 0.74 0.00 (–1.72, 1.58) 0.91 0.85
DLCO /VA , mL/min/
mmHg/L
−0.13 (–0.32, 0.03) 0.01 −0.15 (–0.26, 0.03) 0.10 1.00
LAA% (–960), % 0.12 (–0.61, 1.27) 0.43 1.32 (–4.78, 1.31) 0.0005 0.01
PaO2, mmHg −0.48 (–2.42, 1.80) 0.91 −1.00 (–4.78, 1.32) 0.20 0.29
 Data are expressed as the median (25th, 75th percentile). BMD, bone mineral density in thoracic vertebrae ; BMD/base, percentage change in BMD compared with baseline BMD; FEV 1 , forced 
expiratory volume in 1 second; %FEV 1 , FEV 1 % predicted D LCO /V A , ratio of diffusing capacity to alveolar ventilation; LAA%, percentage of low attenuation area. 
predict the change in BMD, 5 factors that ranked in the 
top 5 on univariate analysis were selected as candidate 
explanatory variables (exacerbation, age, smoking index, 
FEV 1 , and PaO 2 ). As a result, exacerbation and baseline 
PaO 2 were included in this model as explanatory variables 
after stepwise variable selection (R 2 = 0.20, p = 0.007, and 
R 2 = 0.09, p = 0.03, respectively). 
 Discussion 
 In the present study, the analysis showed that a decrease 
in thoracic vertebral BMD was signifi cantly associated 
with COPD exacerbations and baseline PaO 2 , while 
other factors known as risk factors for osteoporosis 
were not associated with the annual change in thoracic 
vertebral BMD. To the best of our knowledge, this is the 
fi rst longitudinal study that investigated the impact of 
exacerbations on comorbidity in COPD patients. 
 In COPD patients, various risk factors, such as low 
BMI, smoking, age, inactivity, systemic infl ammation, 
use of systemic corticosteroids ( 3 ), and LAA%, can be 
associated with osteoporosis ( 5 ). Although most of 
them are still controversial, only LAA% ( 5,6 ) and BMI 
( 5 , 24 ) has been confi rmed to correlate with BMD in 
cross-sectional studies. Osteoporosis is known as one of 
the common systemic manifestations in COPD ( 3 ), but 
the pathogenesis of osteoporosis in COPD patients has 
not been fully understood. Considering our result that 
the exacerbation frequency was signifi cantly correlated 
with the decrease in thoracic vertebral BMD, the factors 
involved in exacerbations could be precipitating key fac-
tors and cause the adverse eff ect. 
 Of these factors, systemic infl ammation is thought 
to play an important role in the progression of osteo-
porosis in COPD patients ( 3 , 25 ). In fact, tumor necro-
sis factor α (TNF-α) and interleukin-6 (IL-6) have been 
reported to be associated with osteoporosis in COPD 
patients ( 26 ), and both factors are known to stimulate 
osteoclasts and increase bone resorption through 
RANKL-mediated bone resorption  in vitro ( 27 ). In 
patients with exacerbations, the levels of various pro-
infl ammatory markers, such as IL-6, were reported to 
be elevated ( 14 ). Th e elevated systemic infl ammatory 
markers, especially TNF-α and IL-6, in patients with 
Figure 2.  Annual change in thoracic vertebral BMD in patients without / with a 
history of exacerbations. Figure 2-1 Annual absolute change in thoracic vertebral 
BMD in patients without / with a history of exacerbations (ΔBMD (mg/ml·year): 
−0.30 versus −3.78, p = 0.01). Figure 2-2. Annual percentage change in thoracic 
vertebral BMD in patients without / with a history of exacerbations based on baseline 
BMD. (ΔBMD/base (mg/ml·year): −0.60 versus −5.41, p = 0.02). The horizontal line 
is the median value, the box is the interquartile range, and the whiskers indicate 
the range, excluding outlying and extreme values (i.e., points with values ≥1.5 box 
lengths from the upper or lower limits of the box). BMD, bone mineral density; 
ΔBMD, annual change in thoracic BMD; ΔBMD/base, annual percentage change in 
















Figure 3.   Annual emphysematous change represented as LAA% on CT in patients 
without / with a history of exacerbations. (LAA (%): 0.12 versus 1.32, p = 0.01) 
The horizontal line is the median value, the box is the interquartile range, and the 
whiskers indicate the range, excluding outlying and extreme values (i.e., points 
with values ≥1.5 box lengths from the upper or lower limits of the box). LAA, low 
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exacerbations might have caused the deterioration in 
BMD in the present study. Further study is necessary 
to explore these ideas. 
 It has been suggested that use of systemic steroids 
during exacerbations is one of the precipitating factors, 
but in the present study, only 1 of 13 patients with a his-
tory of exacerbations received systemic corticosteroid 
treatment. Even excluding this case, the study yielded the 
same conclusion. Th us, in clinical practice, it is impor-
tant to pay attention to the patients who have a history 
of frequent exacerbations and treat them because they 
have a greater risk for osteoporosis progression, even 
if they do not receive systemic corticosteroids during 
exacerbations. 
 Multivariate analysis revealed that baseline PaO 2 was 
associated with the BMD decline independently of a his-
tory of exacerbations. Although no studies have shown 
that hypoxemia is associated with osteoporosis, baseline 
hypoxemia may refl ect the patients’ dyspnea that causes 
inactivity, a risk factor for osteoporosis. Alternately, 
hypoxemia itself has adverse eff ects on osteoporosis in 
COPD patients ( 28 ). To confi rm this fi nding and causal 
association, information about dyspnea and activity 
should be assessed in a future study. 
 We performed a preliminary study of the eff ect of 
osteoporosis therapy on the change in thoracic verte-
bral BMD. To explore the eff ect of osteoporosis ther-
apy on BMD, we measured the change in BMD in 18 
patients with a history of exacerbations using the same 
method as in the present study (online supplement 
e-Table  1 ). Osteoporosis therapy signifi cantly improved 
the decrease in BMD compared to no osteoporosis ther-
apy in patients with a history of exacerbations (p = 0.002, 
online supplement e-Table  2 ). Th ese results suggest the 
potential of osteoporosis therapy, especially in patients 
with a history of exacerbations. Th is fi nding should be 
investigated in a future study. 
 Th is study had several limitations. First, the sample 
size was small. However, this was a single center study 
using only one scanner, so that the instability of CT scan-
ners was less problematic than in multicenter studies. 
 In addition, exacerbations were prospectively 
recorded by at least two respiratory physicians who were 
unaware of CT data. Th ese advantages were thought suf-
fi cient to overcome the small sample size. Moreover, one 
large observational study, the Evaluation of COPD Lon-
gitudinally to Identify Predictive Surrogate End-points 
study (ECLIPSE study), showed that the co-existence 
of osteoporosis was associated with the occurrence of 
exacerbations in a cross-sectional cohort ( 29 ). However, 
they did not examine the infl uence of exacerbations on 
osteoporosis progression. Th e fi ndings in the present 
longitudinal study further deepen our understanding 
of the relationship between COPD exacerbations and 
osteoporosis progression that ECLIPSE suggested. In 
the present study we could detect the progression of 
LAA in those who have a history of exacerbations, but 
couldn’t detect the decline in FEV 1 . It is partly because 
this study was small sample study. 
 Second, BMD in the present study was calculated on 
the chest CT data using our formula that was validated 
in our previous report ( 5 ). Th e data of the present study 
did not include Dual Energy X-ray Absorptiometry 
(DEXA), which is the standard method to estimate BMD. 
Th e lack of DEXA data could be a limitation, but it has 
been reported that CT scan density showed a highly sig-
nifi cant positive correlation with pathological measure-
ments of vertebral bone density ( 30 ). As described in 
the introduction section BMD of the vertebra assessed 
by chest CT scan is clinically useful to predict vertebral 
compression fractures that could deteriorate pulmonary 
functions. Moreover, chest CT scan can detect emphy-
sematous change (LAA) and BMD simultaneously with-
out additional X-ray exposure by DEXA. 






 Age –0.18 0.26
 Body mass index –0.04 0.80
 Smoking history 0.20 0.20
 FEV1 absolute 0.32 0.04
 %FEV1 predict 0.11 0.49
 DLCO /VA 0.16 0.30
 LAA% (-960) 0.03 0.86
 PaO2 0.29 0.07
Annual change
 Frequency of excerbation –0.37 0.02
 ΔFEV1 –0.16 0.32
 Δ%FEV1 0.00 0.98
 ΔBMI 0.05 0.75
 ΔLAA%(-960) –0.10 0.53
 ΔPaO2 0.22 0.20
 
 Relationships were assessed by Spearman’s rank correlation test. BMD, bone mineral 
density; FEV 1 , forced expiratory volume in 1 second; %FEV 1 , FEV 1 % predicted; D LCO /V A , 
ratio of diffusing capacity to alveolar ventilation; LAA%, percentage of low attenuation 
area Δ means annual change in each variables. 
 Table 5.  Stepwise multivariate regression analysis showing the relative 
contribution of each variable to predict the change in BMD 
 Coeffi cient p-value R2
Intercept
−0.094
History of exacerbations, yes:no
−0.013 0.007 0.20
PaO2, mmHg 0.001 0.03 0.09
Cumulative R2   0.30
 Exacerbation (two categories: the presence versus absence of a history of exacerba-
tions), age, smoking history, baseline FEV 1 , and PaO 2 were included as candidate 
independent variables. After stepwise variable selection, baseline factors (age, smoking 
history and FEV 1 ) were excluded. 
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 Th ird the data of the present study subjects lack some 
confounding factors that could aff ect BMD, for example 
activity, diet intake (calcium and vitamin D intake), and 
loss of fat-free mass, since it has been suggested that 
inactivity could cause osteoporosis in COPD patients 
( 31 ). Th e present study did not include some markers of 
bone metabolism (for example values for 25-hydroxyvi-
tamin D) and systemic infl ammation either. Future 
research is needed to assess the eff ect of other factors 
that were lacking in the present study and to clarify the 
mechanism of osteoporosis progression with COPD 
exacerbations. 
 Conclusions 
 In conclusion, the present study demonstrated that 
the decrease in thoracic vertebral BMD was greater in 
patients with a history of exacerbations than in those 
without a history of exacerbations. Th ese data suggest 
that osteoporosis progression should be evaluated in 
COPD patients, especially in those with a history of fre-
quent exacerbations. 
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